2025 Q4 -tulosraportti
Vain PDF
75 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sitten · Muokattupersonally I'm out again but still at a loss sold my 70000 pcs- last week I still believe the small ones panic so everything goes down all the time before year- 2030 I keep an eye on it every day my belief is now at 6 to 8 kr. rarely 9 kr.
I won't say you made a mistake, but I must say it was a strange time. After the emission shares came onto the market, circio jumped to around 8.6. Many short-term investors probably used the opportunity for a quick profit. Since then it fell to around 7.4 and has traded around between 7.36 and approx 8. Every time it goes down to the 7.3-7.4 area, buyers come and say that this is too cheap. Every time it reaches 7.8, sellers say that this is good enough. There is a balance between buyers and sellers and the volume is relatively low. Then we know that data is coming. It does NOT necessarily have to be good data, but based on the statements from Wicklund regarding the feasibility study and other topics, it is not unlikely at least. In vitro Car T poc is indeed announced for q2, which ends tomorrow. So the market is in balance. We can get CarT poc as early as tomorrow, and other good news going forward, which can give a real jump. If you believed in the case a week ago, or a month ago, then nothing negative has happened. Only sale of "surplus shares" from the emission. And we are closer to news.
·2 t sitten · MuokattuCan Circio and GenAssist collaborate with Israeli researchers to cure ALS ? https://www.nature.com/articles/s41593-025-02062-6 1 Researchers in Israel discovered that muscle cells normally send small RNA molecules called microRNA-126 (miR-126) over to nerve cells. This molecule prevents a toxic accumulation of the protein TDP-43. In ALS patients, the muscles stop producing enough miR-126, which leads to nerve cells dying and paralysis. When researchers administered miR-126, the disease stopped, and the nerves began to regenerate. This is where Circio and GenAssist come in and can save lives. 2. Since the problem in ALS starts with the muscles not producing enough miR-126, gene therapy must be delivered directly there. GenAssist develops tissue-specific AAV vectors and directs the medicine directly to the muscles that need to resume the production of miR-126. 3.. circVec can be inserted into the muscle cells to function as continuously producing high levels of the missing miR-126. So, in summary.. Delivery: A medicine is injected into the ALS patient. GenAssist's AAV shell ensures that the medicine navigates directly to the muscle tissue. Production: Inside the muscle cells, Circio's circVec is unpacked and begins to produce circular RNA that codes for microRNA-126 in large quantities, and over a very long time. Treatment: The muscle cells package this miR-126 molecule into small vesicles and send it across the synapse to the damaged nerve cells. Result: The toxic accumulation of TDP-43 in the nerves is stopped, the degeneration of nerve cells ceases, and the patient avoids (or reverses) the paralysis.
·2 t sittenAt 16:25:04, 102,702 shares are sold for 7.45. No news. I can well understand those who buy, but what is the motive of those who sell? Profit taking? Fear of a further downturn? The dip at the end of the day recurs as a pattern. I'm willing to bet a lot that none of the sellers know anything at all about the company that the rest of us don't know. For a poor soul who isn't plagued by so much fear and who believes in the company, this is difficult to understand. Perhaps I see an opportunity for a little profit from the 7.45 sellers if the price starts to fall tomorrow morning. Then it went a bit better for those who sold for 7.79 in the middle of the day. Could it be smart for Daytraders to sell a few hours earlier?
Traders should always close their books at the end of the day. Some days they are in profit and other days they are in loss. But when the clock strikes, all books should be closed.
·5 t sittenERIK JUST REVEALED THE STRATEGY BEHIND ALL THE COLLABORATIONS. 🧩🔑 New interview with Wiklund out — and he explains something people have misunderstood. Many think: "why does Circio enter into so MANY collaborations? Isn't it spreading itself too thin?" Erik turns it on its head. The biggest bottleneck in THE ENTIRE industry is not the molecule. It's delivery. 🚚 How do you get the payload to the right tissue — heart, brain, immune cells — without ending up in the liver or triggering toxicity? He says it outright: countless advanced technologies have failed, not because the molecule was bad, but because they lacked a delivery that worked. 💀 And here's the key: 🔑 No SINGLE company can solve delivery alone. That's why Circio builds relationships with the best delivery groups early and broadly — Tcelltech, Acuitas, TraffikGene, top-5 pharma. It's not spreading itself thin. It's securing access to the sharpest vectors in the industry, before competitors do. 🎯 circVec is the payload that makes the expression 40-50x better. The partners bring the pathways into the body. Put them together, and you have something no one has alone. 🤝 And that's why they start with AAV: proven in clinic, established production, fastest and lowest risk to proof-of-concept. Discipline, not coincidence. ♟️ Every deal you've seen suddenly makes sense. It's one strategy. And it's rolling. 🔥 We know what we own. ♟️🧱🍷.
·6 t sittenWill there be news tomorrow?16 ääntä 2 päivää 17 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
75 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · Muokattupersonally I'm out again but still at a loss sold my 70000 pcs- last week I still believe the small ones panic so everything goes down all the time before year- 2030 I keep an eye on it every day my belief is now at 6 to 8 kr. rarely 9 kr.I won't say you made a mistake, but I must say it was a strange time. After the emission shares came onto the market, circio jumped to around 8.6. Many short-term investors probably used the opportunity for a quick profit. Since then it fell to around 7.4 and has traded around between 7.36 and approx 8. Every time it goes down to the 7.3-7.4 area, buyers come and say that this is too cheap. Every time it reaches 7.8, sellers say that this is good enough. There is a balance between buyers and sellers and the volume is relatively low. Then we know that data is coming. It does NOT necessarily have to be good data, but based on the statements from Wicklund regarding the feasibility study and other topics, it is not unlikely at least. In vitro Car T poc is indeed announced for q2, which ends tomorrow. So the market is in balance. We can get CarT poc as early as tomorrow, and other good news going forward, which can give a real jump. If you believed in the case a week ago, or a month ago, then nothing negative has happened. Only sale of "surplus shares" from the emission. And we are closer to news.
- ·2 t sitten · MuokattuCan Circio and GenAssist collaborate with Israeli researchers to cure ALS ? https://www.nature.com/articles/s41593-025-02062-6 1 Researchers in Israel discovered that muscle cells normally send small RNA molecules called microRNA-126 (miR-126) over to nerve cells. This molecule prevents a toxic accumulation of the protein TDP-43. In ALS patients, the muscles stop producing enough miR-126, which leads to nerve cells dying and paralysis. When researchers administered miR-126, the disease stopped, and the nerves began to regenerate. This is where Circio and GenAssist come in and can save lives. 2. Since the problem in ALS starts with the muscles not producing enough miR-126, gene therapy must be delivered directly there. GenAssist develops tissue-specific AAV vectors and directs the medicine directly to the muscles that need to resume the production of miR-126. 3.. circVec can be inserted into the muscle cells to function as continuously producing high levels of the missing miR-126. So, in summary.. Delivery: A medicine is injected into the ALS patient. GenAssist's AAV shell ensures that the medicine navigates directly to the muscle tissue. Production: Inside the muscle cells, Circio's circVec is unpacked and begins to produce circular RNA that codes for microRNA-126 in large quantities, and over a very long time. Treatment: The muscle cells package this miR-126 molecule into small vesicles and send it across the synapse to the damaged nerve cells. Result: The toxic accumulation of TDP-43 in the nerves is stopped, the degeneration of nerve cells ceases, and the patient avoids (or reverses) the paralysis.
- ·2 t sittenAt 16:25:04, 102,702 shares are sold for 7.45. No news. I can well understand those who buy, but what is the motive of those who sell? Profit taking? Fear of a further downturn? The dip at the end of the day recurs as a pattern. I'm willing to bet a lot that none of the sellers know anything at all about the company that the rest of us don't know. For a poor soul who isn't plagued by so much fear and who believes in the company, this is difficult to understand. Perhaps I see an opportunity for a little profit from the 7.45 sellers if the price starts to fall tomorrow morning. Then it went a bit better for those who sold for 7.79 in the middle of the day. Could it be smart for Daytraders to sell a few hours earlier?Traders should always close their books at the end of the day. Some days they are in profit and other days they are in loss. But when the clock strikes, all books should be closed.
- ·5 t sittenERIK JUST REVEALED THE STRATEGY BEHIND ALL THE COLLABORATIONS. 🧩🔑 New interview with Wiklund out — and he explains something people have misunderstood. Many think: "why does Circio enter into so MANY collaborations? Isn't it spreading itself too thin?" Erik turns it on its head. The biggest bottleneck in THE ENTIRE industry is not the molecule. It's delivery. 🚚 How do you get the payload to the right tissue — heart, brain, immune cells — without ending up in the liver or triggering toxicity? He says it outright: countless advanced technologies have failed, not because the molecule was bad, but because they lacked a delivery that worked. 💀 And here's the key: 🔑 No SINGLE company can solve delivery alone. That's why Circio builds relationships with the best delivery groups early and broadly — Tcelltech, Acuitas, TraffikGene, top-5 pharma. It's not spreading itself thin. It's securing access to the sharpest vectors in the industry, before competitors do. 🎯 circVec is the payload that makes the expression 40-50x better. The partners bring the pathways into the body. Put them together, and you have something no one has alone. 🤝 And that's why they start with AAV: proven in clinic, established production, fastest and lowest risk to proof-of-concept. Discipline, not coincidence. ♟️ Every deal you've seen suddenly makes sense. It's one strategy. And it's rolling. 🔥 We know what we own. ♟️🧱🍷.
- ·6 t sittenWill there be news tomorrow?16 ääntä 2 päivää 17 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
75 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · Muokattupersonally I'm out again but still at a loss sold my 70000 pcs- last week I still believe the small ones panic so everything goes down all the time before year- 2030 I keep an eye on it every day my belief is now at 6 to 8 kr. rarely 9 kr.I won't say you made a mistake, but I must say it was a strange time. After the emission shares came onto the market, circio jumped to around 8.6. Many short-term investors probably used the opportunity for a quick profit. Since then it fell to around 7.4 and has traded around between 7.36 and approx 8. Every time it goes down to the 7.3-7.4 area, buyers come and say that this is too cheap. Every time it reaches 7.8, sellers say that this is good enough. There is a balance between buyers and sellers and the volume is relatively low. Then we know that data is coming. It does NOT necessarily have to be good data, but based on the statements from Wicklund regarding the feasibility study and other topics, it is not unlikely at least. In vitro Car T poc is indeed announced for q2, which ends tomorrow. So the market is in balance. We can get CarT poc as early as tomorrow, and other good news going forward, which can give a real jump. If you believed in the case a week ago, or a month ago, then nothing negative has happened. Only sale of "surplus shares" from the emission. And we are closer to news.
- ·2 t sitten · MuokattuCan Circio and GenAssist collaborate with Israeli researchers to cure ALS ? https://www.nature.com/articles/s41593-025-02062-6 1 Researchers in Israel discovered that muscle cells normally send small RNA molecules called microRNA-126 (miR-126) over to nerve cells. This molecule prevents a toxic accumulation of the protein TDP-43. In ALS patients, the muscles stop producing enough miR-126, which leads to nerve cells dying and paralysis. When researchers administered miR-126, the disease stopped, and the nerves began to regenerate. This is where Circio and GenAssist come in and can save lives. 2. Since the problem in ALS starts with the muscles not producing enough miR-126, gene therapy must be delivered directly there. GenAssist develops tissue-specific AAV vectors and directs the medicine directly to the muscles that need to resume the production of miR-126. 3.. circVec can be inserted into the muscle cells to function as continuously producing high levels of the missing miR-126. So, in summary.. Delivery: A medicine is injected into the ALS patient. GenAssist's AAV shell ensures that the medicine navigates directly to the muscle tissue. Production: Inside the muscle cells, Circio's circVec is unpacked and begins to produce circular RNA that codes for microRNA-126 in large quantities, and over a very long time. Treatment: The muscle cells package this miR-126 molecule into small vesicles and send it across the synapse to the damaged nerve cells. Result: The toxic accumulation of TDP-43 in the nerves is stopped, the degeneration of nerve cells ceases, and the patient avoids (or reverses) the paralysis.
- ·2 t sittenAt 16:25:04, 102,702 shares are sold for 7.45. No news. I can well understand those who buy, but what is the motive of those who sell? Profit taking? Fear of a further downturn? The dip at the end of the day recurs as a pattern. I'm willing to bet a lot that none of the sellers know anything at all about the company that the rest of us don't know. For a poor soul who isn't plagued by so much fear and who believes in the company, this is difficult to understand. Perhaps I see an opportunity for a little profit from the 7.45 sellers if the price starts to fall tomorrow morning. Then it went a bit better for those who sold for 7.79 in the middle of the day. Could it be smart for Daytraders to sell a few hours earlier?Traders should always close their books at the end of the day. Some days they are in profit and other days they are in loss. But when the clock strikes, all books should be closed.
- ·5 t sittenERIK JUST REVEALED THE STRATEGY BEHIND ALL THE COLLABORATIONS. 🧩🔑 New interview with Wiklund out — and he explains something people have misunderstood. Many think: "why does Circio enter into so MANY collaborations? Isn't it spreading itself too thin?" Erik turns it on its head. The biggest bottleneck in THE ENTIRE industry is not the molecule. It's delivery. 🚚 How do you get the payload to the right tissue — heart, brain, immune cells — without ending up in the liver or triggering toxicity? He says it outright: countless advanced technologies have failed, not because the molecule was bad, but because they lacked a delivery that worked. 💀 And here's the key: 🔑 No SINGLE company can solve delivery alone. That's why Circio builds relationships with the best delivery groups early and broadly — Tcelltech, Acuitas, TraffikGene, top-5 pharma. It's not spreading itself thin. It's securing access to the sharpest vectors in the industry, before competitors do. 🎯 circVec is the payload that makes the expression 40-50x better. The partners bring the pathways into the body. Put them together, and you have something no one has alone. 🤝 And that's why they start with AAV: proven in clinic, established production, fastest and lowest risk to proof-of-concept. Discipline, not coincidence. ♟️ Every deal you've seen suddenly makes sense. It's one strategy. And it's rolling. 🔥 We know what we own. ♟️🧱🍷.
- ·6 t sittenWill there be news tomorrow?16 ääntä 2 päivää 17 tuntia jäljelläLiity Nordnet Socialiin osallistuaksesi kyselyyn
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt